Is Edwards Lifesciences (EW) a risky stock?
As of July 21, 2026, Clavix grades Edwards Lifesciences (EW) B+ for risk, a composite score of 86 out of 100 on an A+ to F scale, which puts EW in the "low risk" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind EW's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how EW scores on each, as of July 21, 2026.
What's moving EW's risk right now
Company-specific signals Clavix flags behind EW's current grade, drawn from recent news and filings as of July 21, 2026.
Edwards paid a $10M fine to the FTC over its JC Medical acquisition and must set up a compliance program. The penalty is small relative to its size, but the new program adds costs and signals closer FTC rating update of future deals.
Q2 earnings are the next big catalyst, with double-digit revenue growth expected. Truist raised its price target but kept a 'hold' rating, suggesting tempered confidence despite the improved outlook.
What a B+ grade means
On the Clavix A+ to F scale, EW's composite of 86 falls in the A band (80–100), read as "low risk." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell EW or any security. Grades are risk indicators, not predictions of return. Data may be delayed.